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Tyrosine kinaseMyxoma (MYXV) and vaccinia (VACV) viruses have recently emerged as potential oncolytic agents that can
infect and kill different human cancer cells. Although both are structurally similar, it is unknown whether the
pathway(s) used by these poxviruses to enter and cause oncolysis in cancer cells are mechanistically similar.
Here, we compared the entry of MYXV and VACV-WR into various human cancer cells and observed
signiﬁcant differences: 1 — low-pH treatment accelerates fusion-mediated entry of VACV but not MYXV, 2 —
the tyrosine kinase inhibitor genistein inhibits entry of VACV, but not MYXV, 3 — knockdown of PAK1
revealed that it is required for a late stage event downstream of MYXV entry into cancer cells, whereas PAK1
is required for VACV entry into the same target cells. These results suggest that VACV and MYXV exploit
different mechanisms to enter into human cancer cells, thus providing some rationale for their divergent
cancer cell tropisms.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Poxviruses are large enveloped dsDNA viruses that replicate
exclusively in the cytoplasm of infected cells (Moss, 2007). Histori-
cally, speciﬁc members of the different poxvirus genera have been
more intensively studied than others because of their implications in
human or veterinary diseases, or for use as vaccines, vectors or
platforms for diverse therapies. For instance, variola virus (VARV),
from the genus Orthopoxvirus, has been extensively studied as the
causative agent of smallpox. VARV was eventually eradicated by
vaccination with vaccinia virus (VACV), another related poxvirus of
the genus Orthopoxvirus (Moss, 2007). VACV is one of the best studied
and well characterized poxviruses, which has been used as a proto-
typical model to investigate poxvirus biology in general.
Recently, VACV has emerged as a potential oncolytic agent because
of its rapid life cycle, strong target cell killing activity, inherent ability
to preferentially replicate within tumor tissues (particularly for
attenuated variants of VACV), large cloning capacity, well deﬁned
molecular biology, and its capacity to infect a variety of human cancertypes (Kirn and Thorne, 2009; Thorne, 2008). A second poxvirus
called Myxoma virus (MYXV), from the genus Leporipoxvirus, has also
emerged as a potential oncolytic agent for treatment of human
cancers (Stanford and McFadden, 2007). In contrast to VACV, which
can productively infect a wide range of mammalian hosts, MYXV, can
infect only lagomorphs. In European rabbits (Oryctolagus cuniculus),
MYXV causes a lethal disease called myxomatosis (Fenner and
Ratcliffe, 1965; Stanford et al., 2007). Although MYXV does not
induce any known pathology in humans, or any other non-lagomorph
host, this virus can efﬁciently replicate in vitro in a variety of trans-
formed human cancer cells lines (Barrett et al., 2007a; Wang et al.,
2006; Woo et al., 2008). The ability of MYXV to speciﬁcally infect and
clear human cancer tissues in vivo has also been conﬁrmed in immu-
nodeﬁcient mouse models using various xenografted human tumors
(Lun et al., 2005, 2007; Wu et al., 2008). Because it has not been
reported to induce any toxicity for humans, MYXV has also emerged
as a promising candidate for virotherapy to treat a variety of human
cancers, however unlike VACV, the molecular characteristics of MYXV
infection have not been completely characterized.
One of the key tropism steps that can inﬂuence the ability of an
oncolytic virus to distinguish normal cells from tumor cells is virus entry.
Thus, elucidating and comparing the entrymechanism(s) used byMYXV
and VACV to gain entry into human cancer cells is critical for advancing
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of studies have shed light on the mechanism(s) used by VACV to bind
and enter into host mammalian cells, the majority of which have been
performedwith the intracellularmature virion (MV) formofVACV, since
this is themost abundant and stable infectious form (Moss, 2006). Initial
binding of VACV MVs to mammalian cells occurs by mechanisms that
can be dependent on either cell surface glycosaminoglycans (GAGs) or
other still-unidentiﬁed cellular moieties (Carter et al., 2005; Chiu et al.,
2007; Chung et al., 1998, 2005; Foo et al., 2009; Hsiao et al., 1999).
Studies using electron microscopy originally demonstrated that the
VACVMVs from theWestern Reserve (WR) andmodiﬁed vaccinia virus
Ankara (MVA) strains enter cells by direct fusion with the plasma
membrane (Carter et al., 2005). Later, it was conﬁrmed that the fusion of
VACV MV to the plasma membrane can occur at neutral pH, and is
mediated by amulti-protein fusion complex carried by the virion (Moss,
2006). The number of viral proteins that comprise the poxviral entry–
fusion complex (EFC) has continued to grow. For example, Satheshku-
mar and Moss (2009) provided recent evidence that VACV O3L
(VACVWR069.5), a short open reading frame (ORF) of just 35 amino
acids, which possesses orthologs in MYXV (Cameron et al., 1999) and
molluscum contagiosum virus (Senkevich et al., 1997), is the newest
identiﬁed integral component of the EFC, required for MV entry and
membrane fusion.
Additionally, poxvirus MVs can also utilize a low-pH endosomal
entry pathway (Townsley et al., 2006) but, interestingly, some strains
of VACV cannot exploit this latter pathway (Bengali et al., 2009). A
recent report suggests that VACV MV entry uses macropinocytosis, a
transient growth factor-induced, and actin-dependent endocytic
mechanism, which is utilized by large particles such as bacteria,
apoptotic bodies, necrotic cells and viruses to penetrate into the
cytoplasm of mammalian cells (Mercer and Helenius, 2008). The
induction of macropinocytosis is preceded by the rapid activation of
signaling pathways via tyrosine kinase receptors that ultimately
trigger re-arrangements of actin ﬁlaments at the plasma membrane,
which favors the internalization of interacting particles (Mercer and
Helenius, 2009).
In contrast to VACV, the mechanism(s) whereby MYXV enters
mammalian cells have yet to be studied in detail, although the known
virus-encoded members of the viral EFC identiﬁed in VACV are highly
conserved in MYXV. With this in mind, we ﬁrst sought to establish if
there were any differences in the entry mechanisms between the
MYXV Lausanne (MYXV-Lau) strain and the VACV Western Reserve
(VACV-WR) strain, using several human cancer cells as a model
system. We report that substantial differences exist between these
viruses with regard to the effects of low pH, and the requirement for
endosomal acidiﬁcation for entry. We used speciﬁc kinase inhibitors
to demonstrate differences in the drug sensitivity to MV entry of both
viruses. Speciﬁcally, we found that genistein, a tyrosine kinase
inhibitor that blocks macropinocytosis, speciﬁcally inhibits the entry
of MV particles from VACV, but not MYXV, into the same target cancer
cells. These ﬁndings will further help our understanding of the various
oncolytic mechanisms exploited by poxviruses and facilitate their
development for oncolytic virotherapy.
Results
Replication of MYXV and VACV is cell-type dependent
Both MYXV and attenuated variants of VACV are potential
oncolytic virus candidates for treatment of human cancers. In
order to understand the mechanism of entry used by both viruses
in various human cancer cells, we started this study comparing the
infectivity of MYXV and VACV in several selected human cancer cell
lines: A549 (lung carcinoma cells), HeLa (cervical carcinoma), Panc1
(pancreatic carcinoma) and BJAB (EBV-negative Burkitt B-cell
lymphoma). We ﬁrst used ﬂuorescence microscopy to compare theability of MYXV and VACV tagged with both EGFP (early/late
expression) and Tomato Red (late expression only) to infect and
spread within different cancer cell types. To do this, the indicated
cells were infected with the recombinant vMyx-GFP-TrFP or VACV-
GFP-TrFP at a MOI of 0.1 and evaluated by ﬂuorescence microscopy
48 h post-infection (hpi). In each case, expression of GFP was a
measure of early/late viral gene expression and TrFP was a measure
of late gene expression only. We observed signiﬁcant differences in
infection progression by the viruses in some of the cancer cell types
(Fig. 1). For instance, in A549 and HeLa cells, both MYXV (Fig. 1A)
and VACV (Fig. 1B) appeared to initiate a permissive infection and
underwent normal cell-to-cell spread. As well, the expected increase
in the infectious progeny virus was observed for both viruses from
A549 cells (Fig. 2A), which was comparable to titers in the control
BGMK cells (Fig. 2B). In contrast, ﬂuorescence microscopy analysis
revealed the expression of both EGFP and TrFP from vMyx-GFP-TrFP
and VACV-GFP-TrFP infection of BJAB (Figs. 1A and B, respectively),
however, single step growth curves showed that infection of BJAB
cells with MYXV did not produce new infectious virions while
infection of these cells with VACV produced signiﬁcantly fewer new
virions than BGMK cells (Fig. 2C). The most notable differences
between MYXV and VACV were observed with Panc1 cells, which
supported productive replication for VACV but were completely
nonpermissive for MYXV (Figs. 1A, B and 2D). Taken together, these
results demonstrate that these viruses can differ signiﬁcantly in
terms of gene expression and progeny virus production in certain
speciﬁc human cancer cells.
MYXV entry into cancer cells, unlike VACV, is not stimulated by acidic pH
The entry mechanism(s) used by the mature virions (MVs) of
VACV have been actively investigated in recent years. In this regard,
Vanderplasschen et al. (1998) ﬁrst reported that, while VACVMVs can
enter cells by fusing with the plasma membrane at neutral pH, VACV
EEVs use a low pH as the entry pathway. Further studies conducted by
Townsley et al. (2006) also demonstrated that VACV MVs can use the
endocytic route via low-pH to enter to the cells,. This latter conclusion
is based on the evidence that a brief low-pH treatment (e.g. pH 5.0)
accelerates VACV MV entry into host cells. In contrast, the role of pH
has not been previously tested for MYXV. To determine whether
MYXV entry also exploits this low-pH endosomal route, the rate of
virus entry was quantiﬁed at neutral and acidic pH by measuring
luciferase expression from either vMyx-GLuc (expressing Gaussia
luciferase from a synthetic early/late promoter), or VACV-FLuc
(expressing ﬁreﬂy luciferase from the same promoter). This assay
allowed us to compare the entry kinetics of each virus under different
conditions.
In our initial studies, virus adsorption was synchronized by incu-
bation of either, VACV-FLuc, or vMyx-GLuc to HeLa cells at 4 °C for 1 h.
Then each virus was incubated at 37 °C to allow the synthesis of the
indicated luciferases. Although under these conditions, we were able
to readily measure the VACV-FLuc luciferase activity (Supplemental
Fig. S1C), we did not detect any vMyx-GLuc luciferase activity
(Supplemental Fig. S1A). Next, we tested the ability of both viruses
to enter the cells at room temperature (25 °C), and observed similar
results. Only when the adsorption of MYXV proceeded at 37 °C we
were able to measure any viral luciferase activity (Supplemental Fig.
S1A) indicating successful MYXV entry. To determine if this result was
a peculiarity of HeLa cells, we next tested RK13 cells, a rabbit cell line
permissive for MYXV and VACV. Virus entry was synchronized as
described above. Surprisingly, we obtained the same results with
RK13 cells (Supplemental Fig. S1, panels B and D) as with HeLa cells,
suggesting that in contrast to VACV, MYXV has uniquely different
temperature requirements for either binding and/or entry.
In order to evaluate the effect of low-pH on MYXV entry, puriﬁed
vMyx-GLuc MVs were adsorbed to the cells at 37 °C and then were
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Fig. 2. One-step growth of MYXV and VACV is cell line-speciﬁc. Single growth curves were generated to evaluate the replication of MYXV and VACV in (A) A549, (B) BGMK (C) BJAB
and (D) Panc1 cells. Cells were infected with either vMyx-GFP-TrFP or VACV-GFP-TrFP at a multiplicity of 5.0. Titers are expressed as log PFU/106 cells. The single growth curve for
BGMK was used as a positive control, since this cell line is optimally permissive for both viruses.
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VACV-FLucMVswere adsorbed to the cells at 4 °C and then exposed to
pH 5.0 for 3 min at 37 °C. Consistent with previously reported results,
a brief exposure to pH 5.0 resulted in a modest increase in the rate of
VACV entry into both A549 (Fig. 3C), and HeLa (Fig. 3D) cells. In
contrast, the same treatment actually decreases Gaussia luciferase
expression from vMyx-GLuc in both A549 (Fig. 3A) and HeLa (Fig. 3B)
cells. This difference was not due to adsorption of VACV at 4 °C since
adsorption of this virus at 37 °C yielded comparable results (data not
shown).
Because the pH of the endosome varies from pH 6.0 for early
endosomes to pH 5.0 for late endosomes, we tested the effect of a wide
range of pHs starting from 5.0, 5.5, 6.0, 6.5, 7.0 and 7.4, to determine if
MYXV entry could be activated at an acidic pH higher than 5.0.
Interestingly, we found that pH 7.4 is the optimal pH for MYXV
(Lausanne strain) to enter these cells, and that in contrast to VACV
(WesternReserve strain), lowerpHshave an inhibitory effect onMYXV
entry, with pH 5.0 being the most inhibitory pH (results not shown).
Because activation at low pHs can be time dependent, we measured
luciferase activity at different time points starting at 1, 2, 3, 4, and 5 h
after virus adsorption. Interestingly, we always observed that a low pHFig. 1.MYXV and VACV replication and spread is cell line-dependent. Selected human cancer
TrFP, at a multiplicity of 0.1 (MOI 0.1). At 48 h after infection the formation of foci (for MYhad an inhibitory effect onMYXV entry (results not shown). Therefore,
we conclude that the inhibitory effect on MYXV entry observed at
acidic pHs is time-independent.
Previous studies performed with VACV MVs revealed that the
stimulation of virus entry through low-pH treatments pre- and post-
virus adsorptionwere not additive (Townsley andMoss, 2007).We found
that two consecutive exposures of vMyx-GLuc to pH 5.0 (e.g. one prior
virus adsorption, and the other after virus adsorption) at 37 °C for 3 min
did not increase Gaussia luciferase activity (Fig. S2A). On the other hand,
treatment of VACV-FLucMVs at pH 5.0 followed by adsorption at 4 °C and
then a second exposure to either, pH 7.4 or 5.0 resulted in similar Luc
activities, although two consecutive treatments at pH 5.0 (pre-adsorption
and post-adsorption) resulted in a slight increase in the VACV luciferase
activity (Fig. S2B). Taken together these results suggest that MYXV and
VACV binding and/or entry to at least some human cancer cells occurs by
nonidentical mechanisms.
Finally, to directly address the potential for acid activation of the
fusion machinery, we assessed the ability of MYXV to form syncytia at
lowpH.Our results demonstrate thatMYXV(Lausanne strain), doesnot
form syncytia at low pH (e.g. 4.6) whereas, VACV (Western Reserve
strain), does form syncytia at the acidic pH 4.6, as expected (results notcell lines were infected with the puriﬁed MVs of (A) vMyx-GFP-TrFP, or (B) VACV-GFP-
XV) or plaques (for VACV) was visualized by ﬂuorescence microscopy.
Fig. 3. VACV and MYXV entry into cancer cells is differentially affected by brief low-pH exposure. A549 cells (panels A and C) and HeLa cells (panels B and D) were infected with
vMyx-GLuc (panels A and B) or VACV-FLuc (panels C and D) at a MOI of 5.0 for 1 h. After virus adsorption to the cells, unbound virus was removed and cells were washed with PBS
followed by 3 min treatment in neutral pH (7.4) or low pH (5.0) at 37 °C. Cells were washed in neutral pHmedia and the infectionwas allowed to proceed for different time points (2,
4, and 6 h). At the given time point, cells were assayed for luciferase activity. Data represent the average±standard error of samples in triplicate. Luciferase activity is reported in
light units (LU).
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reporting between VACV-WR and MYXV are biologically signiﬁcant.
Inhibition of endosomal acidiﬁcation affects both MYXV and VACV entry
Above, we have shown that in contrast to VACV entry, MYXV entry
is not accelerated by low-pH treatment, (Fig. 3, Figs. S1 and S2). These
data, however, do not rule out the possibility that MYXV uses an
endocytic pathway as a means to enter cells. Previous studies have
provided evidence for the uptake of VACV via the endocytic pathway
(Townsley and Moss, 2007; Townsley et al., 2006). If MYXV uses the
endocytic pathway, pharmacological inhibition of this pathway by
inhibiting the relevant V-ATPases should also inhibit MYXV entry. To
test this, we treated cells with baﬁlomycin A1 and concanamycin-A,
two speciﬁc inhibitors of the intracellular acidiﬁcation-dependent
enzyme V-ATPase (Bowman et al., 1988; Dröse and Altendorf, 1997;
Klee et al., 1999), and determined the effects this treatment had on
entry of MYXV and VACV (Fig. 4). Interestingly, at neutral pH, a
decrease in the luciferase activity was observed for both viruses
following treatment with either drug in a dose-dependent manner,
conﬁrming previous observations performed with VACV (Townsley
et al., 2006). To determine whether a low-pH treatment of boundMVs
could bypass the inhibitory effect exerted by these drugs, both viruses
were brieﬂy exposed to pH 5.0 at 37 °C for 3 min after binding.Signiﬁcantly, we found that only the inhibition of VACVMV entry was
alleviated under these conditions, while entry of MYXV remained
constitutively blocked. These results not only conﬁrm the ability of
VACV to use the endocytic pathway for entry to cells, but also suggest
the possibility that MYXV exploits the endocytic route to enter into
cancer cells in a fashion that cannot be circumvented by transient
low-pH treatment.
To further access whether MYXV uses the endocytic route as a
means to enter the test cancer cells, the effect on viral entry was
determined following treatment with pepstatin A, which inhibits the
proteolysis of aspartic acid proteases, (Binkert et al., 2006). Interest-
ingly, only a very modest decrease in the luciferase activity for MYXV-
GLuc and VACV-FLuc was observed, suggesting that MYXV infection
does not require the activation of cellular acid-dependent endosomal
proteases to enter cells and initiate early gene expression (results not
shown). These results were somewhat unexpected, since it is well
known that pepstatin A inhibits the proteolysis of aspartic acid
proteases that in turn inhibit endosomal acidiﬁcation (Zaidi et al.,
2007), which should affect signiﬁcantly VACV entry via the endocytic
route. However, Okada et al. (2003) reported that pepstatin A also
displays an alternative role inducing extracellular acidiﬁcation, which
is unrelated to its inhibition of aspartic proteases.We conclude that the
external acidiﬁcation produced via pepstatin does not signiﬁcantly
affect MYXV and VACV entry into these cancer cells.
Fig. 4. Inhibitors of endosomal acidiﬁcation decrease both VACV andMYXV entry. HeLa cells were pre-treatedwith the indicated inhibitor for 1 h at 37 °C.While VACV-FLuc (panels C
and D) was adsorbed to the cells at 4 °C for 1 h, vMyx-GLuc (panels A and B) was adsorbed to the cells at 37 °C for 1 h. Un-adsorbed viruses were removed and cells treated with
either neutral pH (7.4), or acidic pH (5.0) in identical fashion as described elsewhere in this manuscript. Two hours after infection, cells were assayed for luciferase activity. Data
represent the average of triplicates±standard error.
Table 1
Drug inhibitors used for this study.
Inhibitor name and
abbreviation
Description
K252a An ATP analog that has been described as a serine/
threonine kinase inhibitor and as a selective and potent
inhibitor of different members of the tyrosine kinase
family (Morotti et al., 2002; Tapley et al., 1992)
Tyrphostin (AG17) Tyrosine kinase inhibitor that decreases the levels of
p21 in OCI-Ly8 immunoblastic lymphoma cell line.
Induces apoptosis (Palumbo et al., 1997)
Wortmannin (WORT) PI3-Kinase inhibitor (Chen and Wang, 2001)
Cytochalasin-D (CTC-D) An actin-disrupting drug that affects macropinocytosis
(Mercer and Helenius, 2008; Stevenson and Begg, 1994)
Brefeldin A (BFA) Fungal macrocyclic lactone that affects the activation of
the small GTPase Arf1 (Damm et al., 2005)
5-(N-Ethyl-N-isopropyl)-
amiloride (EIPA)
Blocks Na+/H+ exchanger and a known inhibitor of
macropinocytosis (Fretz et al., 2006; Nakase et al., 2004)
Staurosporin (STAU) A protein kinase C (PKC) inhibitor and an inducer of
apoptosis (Constantinescua et al., 1991; Wasilenko et al.,
2001)
Genistein Tyrosine kinase inhibitor (soy ﬂavonoid) that blocks
many different viruses at various stages (Andres et al.,
2009)
Blebbistatin (BB) A myosin II-depending inhibitor that inhibits VACV
entry (Mercer and Helenius, 2008)
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cancer cells
Recent studies have suggested that VACVMVs usemacropinocytosis
to enter host cells although the exact role of the virion phospholipids
and “apoptosis mimicry” in this process remains controversial (Mercer
and Helenius, 2008; Laliberte and Moss, 2009). Macropinocytosis, an
actin-dependent endocytic process, is characterized by changes in the
dynamics of actin ﬁlaments, which produce morphological changes of
the plasmamembrane. Macropinocytosis is induced by external stimuli
that trigger the activation of receptor tyrosinekinases, depending on the
size and nature of the stimulating ligands. In addition to this, re-
arrangements of actin are regulated via the activation of phosphatidy-
linositol (PI) 3-kinase, and the Rho-family of small GTPases (Mercer and
Helenius, 2009). The use of inhibitors that target either the kinases
involved inmacropinocytosis, or actin formation, has shed light into the
mechanism(s) used by VACV MVs to enter host cells. To compare the
effects of these inhibitors on MYXV and VACV entry, a select group of
pharmacological inhibitors that act on a number of targets including
tyrosine and serine–threonine kinases, disruption of actin polymeriza-
tion, and inhibition ofNa+/H+exchange,were tested for their effects on
viral entry (Table 1).
Fig. 5.MYXV and VACV entry is affected differentially by drug inhibitors. Prior to infection, cells HeLa (panels A and C) and A549 (panels B and D) were treated with each indicated
inhibitor at the appropriate concentration during 1 h at 37 °C. Either vMyx-GLuc (panels C and D), or VACV-FLuc (panels A and B) was adsorbed to the cells at 37 °C for 1 h in the
presence of inhibitor. After adsorption, cells were washed and then incubated with media supplemented with the appropriate inhibitor for 1 h. Cells were subsequently assayed for
luciferase activity. Cycloheximide (CHX) was added to the cells to prevent the early viral protein synthesis and serves as an internal control to quantify newly synthesized luciferase.
Data represent the average±standard error of samples in triplicate, and are expressed in light units (LU).
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37 °C, and then virus was adsorbed for 1 h to the respective cell line in
the presence of the inhibitor. After virus adsorption, cells were washed
and incubated at 37 °C for 2 h to allow the synthesis of luciferase and
then assayed for luciferase activity. The results from this drug inhibitor
screen revealed some intriguing differences between VACV and MYXV
(Fig. 5). For example, we found that each virus responded differently to
the tyrosine kinase inhibitor genistein in a cell line independent
manner (Fig. 5, last columns in each panel).While VACV-FLuc entry into
HeLa or A549 cells was dramatically inhibited by genistein (Figs. 5A and
B, last columns marked with an asterisk, respectively), MYXV-GLuc
entry was relatively unaffected by genistein (Figs. 5C, and D, last
columnsmarkedwith an asterisk). To investigate if the divergent effects
of genistein on the two viruses might be kinetic in nature, luciferase
experiments were performed for A549 (Figs. 6A and B) and HeLa
(Figs. 6C andD) cells at different time points. Consistentwith the former
results, genistein did not inhibit MYXV entry at any time point (Figs. 6A
and C)whereas VACV entrywas almost completely eliminated (Figs. 6B
andD). These results clearly demonstrate thatMYXVandVACV responddifferently to genistein, suggesting that the kinase targets of this drug
are uniquely required for the entry and/or early viral gene expression of
VACV, but not MYXV.
Low-pH exposure decreases MYXV entry even in the presence of genistein
Recently, it was demonstrated that the inhibition produced by
genistein on VACV MV entry could be bypassed by transient low-pH
exposure (Mercer and Helenius, 2008) suggesting that, at least for
VACV, this inhibitor blocks virus entry. Here, we have shown that
MYXV entry is instead inhibited by low-pH exposure (Figs. 3A and C)
and that genistein does not signiﬁcantly affect MYXV entry (Fig. 5).
Effect of genistein on MYXV replication at late times
Our luciferase reporter results suggest that genistein speciﬁcally
affects VACV entry but not that of MYXV. To determine if genistein
affects later stages of MYXV replication and progeny virus production,
we ﬁrst analyzed the spread of virus infection in cancer cells in the
Fig. 6. Genistein differentially affects MYXV and VACV entry in a time-independent manner. Kinetic experiments were performed for A549 (panels A and B) and HeLa (panels C and
D). Cells pre-treated with genistein were infected with vMyx-GLuc (panels A and C) or VACV-FLuc (panels B and D) for 1 h, at 37 °C. At the given time points post-infection, luciferase
activity is expressed in light units, (LU).
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GFP-TrFP or VACV-GFP-TrFP at a MOI of 0.1. At 48 hpi, the synthesis of
EGFP and TrFP gene was examined by ﬂuorescence microscopy.
As expected, genistein dramatically inhibited VACV early (EGFP) and
late (TrFP) gene expression, whereas MYXV was not affected
(Fig. 7A). We also measured the effect of genistein on the percent of
EGFP-positive cells of both viruses using ﬂow cytometry following
infection with each virus at a MOI of 0.1. The results demonstrate that
although genistein does not affect the extent of the number of MYXV-
GFP+ cells, it dramatically reduced the percent of vaccinia GFP+ cells
(Fig. 7B).
Next, we investigated the effect of genistein on the replication of
both viruses in a single step growth cycle in HeLa cells infected with
each virus at a MOI of 5.0. Cells were collected at the indicated times
points after infection and the infectious progeny virus titrated on
indicator BSC-40 cells. Although both GFP and TrFP were synthesized
(Fig. 7A), MYXV progeny virus synthesis was essentially blocked by
genistein (Fig. 7C). As expected, VACV progeny were not synthesized
in the presence of genistein (Fig. 7D). These results suggest that,
unlike VACV, the entry of MYXV is not blocked by genistein but this
inhibitor does cause a post-replicative late block to MYXV progeny
virus assembly. In fact, this was demonstrated by two means: (i) the
expression kinetics for representative early and late MYXV and VACV
genes was analyzed by real-time PCR (Supplemental Fig. S3, panels A
and B, respectively), and (ii)Western blot analysis (Supplemental Fig. S4,
panels A and B, respectively), which revealed that genistein differentially
affected early and lateMYXV andVACVprotein synthesis. Taken together,our results demonstrate that genistein inhibits MYXV not at entry, but
rather at a post-entry stage, whereas VACV is blocked by this drug at the
early stage of virus entry.
MYXV, but not VACV, entry into cancer cells is not dependent on PAK1
PAK1 has been reported as an essential cell kinase factor for entry of
VACVMV(Mercer andHelenius, 2008). To determine the requirement for
PAK1 in MYXV entry, we used small interfering RNA (siRNA) to knock
down PAK1 in HeLa cells, which was assessed at the protein level by
Western blot analysis (Fig. 8A, lane 3). Both non-targeting siRNA (NT-
siRNA) (Fig. 8A, lane 2), and untreated cells [Mock (−)], (Fig. 8A, lane 1),
were used as controls. The effect of knocking down PAK1 reduced VACV
early and late gene expression (Fig. 8C) much more extensively than for
MYXV(Fig. 8B). The results obtained forMYXV inHeLa cells are consistent
with previous studies performed with mouse NIH3T3murine ﬁbroblasts,
which revealed that PAK1 is required for a late stage of MYXV replication
downstream of binding and entry (Johnston et al., 2003). To further
conﬁrm that PAK1 is not required for MYXV entry into cancer cells, we
measured luciferase activity for vMyx-GLuc (Fig. 8D) and VACV-FLuc
(Fig. 8E). At 72 h after PAK1 siRNA transfection, HeLa cells were infected
with either vMyx-GLuc or VACV-FLuc at a MOI of 5.0. Two hours post-
infection, cells were assayed for luciferase activity (Figs. 8D and E).
Knockdown of PAK1 caused only modest reduction in MYXV entry
that did not reach signiﬁcance (Fig. 8D), in contrast, VACV entry
was signiﬁcantly decreased (Fig. 8E, last columnmarkedwith an asterisk).
In general, these results demonstrate that PAK1 is required for VACV
Fig. 7. Genistein differentially affects MYXV and VACV. (A) HeLa cells were treated with genistein for 1 h and then infected with vMyx-GFP-TrFP or VACV-GFP-TrFP at a MOI of 1.0.
After 1 h of virus adsorption, cells were incubated in a media containing genistein. Virus propagation was assessed by ﬂuorescence microscopy 72 h post-infection. (B) To measure
cell–cell spread, the percentage of GFP+ cells in untreated (no genistein) and genistein-treated samples was determined by ﬂow cytometry. Cells were infected with each virus at a
MOI of 1.0, trypsinized and ﬁxed in para-formaldehyde before analysis. (C) and (D): To investigate the effect of genistein on MYXV and VACV virus titers, cells were harvested at the
given time points and then lysed by repeated freeze–thawing. Virus titers were determined as described in Materials and methods.
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required for a late stage in MYXV replication, which conﬁrm
previous ﬁndings of our group (Johnston et al., 2003). The speciﬁc
requirement of PAK1 for VACV entry into cancer cells but not
that for MYXV, constitutes another difference between the entry of
these viruses.Discussion
Binding and entry into a cell are key steps for successful viral
replication and progression of infection. It has been reported that
most chordopoxviruses can bind and enter a much wider variety of
mammalian cells in vitro than is predicted based on their host
Fig. 8. Entry of MYXV and VACV into cancer cells is differentially affected by knockdown of PAK1. (A) Representative Western blots conﬁrming PAK1 knock down. HeLa cells were
transfected for 72 h with 50 nM siRNA directed against PAK1 (lane 3), or against a non-targeting siRNA, (NT-siRNA), (lane 2). Untransfected cells are referred as mock (−) (lane 1).
Equal sample loading was conﬁrmed by detection of the housekeeping protein actin. Replication of vMyx-GFP-TrFP (panel B) and VACV-GFP-TrFP (panel C) in HeLa cells was
evaluated by ﬂuorescence microscopy. 72 h after transfection, cells were infected with the recombinant ﬂuorescent viruses at a MOI of 1.0. Formation of MYXV foci, or VACV plaques
was evaluated 48 hpi. Entry of MYXV-GLuc (D) or VACV-FLuc (E) into cells was assessed 72 h post-transfection bymeasuring luciferase activity after 2 h infection with vMyx-GLuc or
VACV-FLuc at a MOI of 5.0.
275N.Y. Villa et al. / Virology 401 (2010) 266–279
276 N.Y. Villa et al. / Virology 401 (2010) 266–279tropisms in vivo, and to date no speciﬁc cell surface receptor for cell
entry by poxviruses has been reliably reported (McFadden, 2005).
However, differences in poxvirus binding and entry have beennoted even
between similar strains of VACV into the same cells (Bengali et al., 2009),
suggesting that the binding and entry stage might indeed play a role in
mediating cellular tropism by poxviruses. This issue is particularly
important for viruses that are being exploited for oncolytic virotherapy,
andmayplayadiscriminatory role inhowsuchvirusesdistinguishnormal
vs cancerous cells.We initiated this study to establish if differencesmight
exist betweenMYXV and VACV in their modes to infect and replicate in a
select test group of human cancer cells. In this regard, we found that
infectionwithMYXV is selectively restrictive to some cancer cells, such as
pancreatic cancer cells (Panc1),whereasVACVcan infect a larger selection
of human cancer cell types. These initial results prompted us to focus on
the early stages of infection, in particular virion entry, with the goal to
establish any differences between these viruses.
The poxviruses MYXV (Lausanne strain), and VACV (WR strain)
exploit nonidentical mechanisms to enter into the same human cancer
cells. Using early promoter driven luciferase expression assays, we
found that entry ofMYXV in cancer cells is uniquely inhibited at lowpH.
In contrast, low-pH treatment signiﬁcantly accelerated VACV entry into
the same cells. Interestingly, the use of inhibitors of endosomal
acidiﬁcation, like baﬁlomycin A1, and concanamycin-A, two inhibitors
of the vacuolar H+-ATPase (Dröse and Altendorf, 1997), reduced both
VACV and MYXV entry in a dose-dependent manner, suggesting that
both viruses utilize an endocytic route of entry. However, they differ
signiﬁcantly in their ability to be stimulated by low pH. VACV, under
low-pH treatment, can overcome the inhibitory effects mediated by
these inhibitors of the endosomal acidiﬁcation,whereasMYXV is unable
to do so.
During poxvirus infection of mammalian cells, rapid cell signaling
events are induced that participate in virus entry, including the activation
of a wide range of tyrosine and serine–threonine kinases (like PAK1),
which were found to play pivotal roles in VACV entry (Mercer and
Helenius, 2008). In this regard, we conﬁrmed that genistein, a soy
isoﬂavonoidanda tyrosinekinase inhibitor, blocksVACVentryas reported
previously (Mercer and Helenius, 2008) but here we demonstrate that
genistein does not inhibit MYXV entry into the same cancer cells.
Nevertheless, genistein is still inhibitory to MYXV replication, but blocks
the virus growth cycle at a later post-entry stage. The fact that genistein
selectively affects VACV but not MYXV entry and alters MYXV replication
only at late stage(s), suggests that this inhibitor may target intracellular
molecules that are differentially required for VACV andMYXV replication.
Mercer and Helenius (2008) reported evidence supporting the effect of
genistein on reducing the phosphorylation of PAK1 and the concomitant
reduction of VACV MV entry. This seemed to be in contrast to a previous
publication by our lab (Johnston et al., 2003) showing that PAK1 was
required forMYXV replication inmouse cells only at later (e.g. post-entry)
stages of virus replication. In this study, we show that blocking PAK1
expression by siRNA was indeed selectively inhibitory to the entry of
VACV, but not MYXV, into the same human cancer cells.
Recent reports have claimed that VACV uses macropinocytosis as
an efﬁcient entry mechanism that allows the virus to subvert the
innate cellular apoptotic response pathway to gain entry into
mammalian cells (Mercer and Helenius, 2008) but the exact role of
externalized phosphatidyl serine on the input virions has been
questioned (Laliberte and Moss, 2009). Since macropinocytosis is an
actin- and tyrosine kinase-dependent mechanism, we tested whether
various inhibitors could selectively block cellular pathways required
for VACV, but not MYXV, entry into human cancer cells. Our data
support a role for genistein in inhibiting VACV at the entry level, while
for MYXV the effect of this inhibitor is not at the entry step but rather
at a much later post-entry level. This result allows us to make a
functional differentiation between these two poxviruses at the level of
entry into cancer cells. The role of isoﬂavones like genistein at
inhibiting the replication of many distinct viruses has been welldocumented, ranging from virus binding, (Andres et al., 2007; Hayashi
et al., 1997) and entry (Kubo et al., 2003; Li et al., 2000; Sharma-Walia
et al., 2004) to virus replication (Evers et al., 2005; Kim et al., 2006;
Robin et al., 2001; Yura et al., 1993), viral protein translation, as well
as the formation of viral glycoproteins complexes (Andres et al.,
2007). Here we show that the kinase targets for genistein are required
at very different levels for VACV (e.g. entry) and MYXV (e.g. late virus
assembly).
Regardless of the mechanism, the results presented here uncover
new insights with regard to entry of poxviruses to cancer cells. This is of
considerable interest because both MYXV and attenuated variants of
VACVare currently beingdeveloped for oncolytic virotherapy, and these
two viruses exhibit very distinct oncolytic properties (Kirn and Thorne,
2009; Stanford andMcFadden, 2007). Establishing themechanism(s) by
whichMYXV and VACV can differentially enter and initiate infections of
human cancer cells and thereby exert oncolysis in different models of
cancer needs to be addressed in future studies.
Materials and methods
Cell culture and infections
All cells used in this study, were grown at 37 °C in a humidiﬁed 5%
CO2 atmosphere. Unless otherwise mentioned, all media used in this
study were always supplemented with 100 μg/mL penicillin–strep-
tomycin, and 2 mM L-glutamine. CV-1 cells (ATCC# CCL-70) were
cultured in Minimum Essential Medium (MEM; Gibco BRL, Grand
Island, NY) supplemented with 1× MEM nonessential amino acids
(Cellgro, Mediatech, Herndon, VA), 1 mM sodium pyruvate and 5%
fetal bovine serum (FBS); (Gibco BRL). The cell lines HeLa (ATCC#
CCL-2), A549 (ATCC# CCL-185), RK13 (ATCC CCL-37), BSC-40 (a
generous gift of Dr. Richard Condit), and BGMK (Wang et al., 2008)
were maintained in Dulbecco's modiﬁed Eagle's medium, (DMEM)
supplemented with 10% FBS. BJAB (a generous gift of Dr. Sankar
Swaminathan) and Panc1 (ATCC# CRL-1469) cells weremaintained in
Iscove's Modiﬁed Dulbecco's Medium (IMDM) (Invitrogen) supple-
mented 20% FBS).
Pharmacological drugs
Unless otherwise noted in the text, each pharmacological inhibitor
was added to the cells 1 h before virus adsorption and maintained
throughout the course of the experiment. The inhibitors blebbistatin
(BB), staurosporine (STAU), wortmannin (WORT), cytochalasin-D
(CTC-D), AG17, K252a, ethylisopropyl amiloride (EIPA), brefeldin A
(BFA), genistein, baﬁlomycin A1, concanamycin-A, cycloheximide
(CHX) and cytosine arabinoside (AraC) were obtained from Sigma-
Aldrich. Pepstatin A was obtained from Fisher.
Viruses
All experiments were performed with MYXV, Lausanne strain, and
VACV, Western Reserve (WR) strain. Recombinant vMyx-GFP-TrFP
expressing both enhanced green ﬂuorescent protein (EGFP) driven by a
synthetic early/late poxvirus promoter and Tomato red ﬂuorescent
protein (TrFP) driven by poxvirus P11 late promoter has been described
previously (Bartee et al., 2009). Recombinant VACV expressing both
EGFP (under synthetic E/L promoter) and TrFP (under P11 late
promoter) was created by an intergenic insertion of the TrFP and
EGFPcassettes into theVACVgenome. Recombinantvaccinia virus (WR)
expressing the ﬁreﬂy luciferase under a synthetic poxvirus early/late
promoter (VACV-FLuc) was generated by Dr. Peter Turner (Turner and
Moyer, 2008) and was a kind gift from Dr. Dick Moyer (Department of
Molecular Genetics and Microbiology, University of Florida).
Recombinant myxoma virus expressing the Gaussia luciferase
driven by a poxvirus synthesis early/late promoter (vMyx-GLuc) was
Table 2
Primers used for real-time PCR.
Gene Primer
Directiona Sequence (5′–3′)
MYXV M-T7 For CGTGGATCAATGTGTGTGAA
MYXV M-T7 Rev CAAGACACGACGTCCAAATC
MYXV SERP-1 For CGTGACGTTTAACTCGGAGA
MYXV SERP-1 Rev CTCGTCTTCATACGAACGGA,
VACV F11L For ACAGGATTCGTCATTCCAGA
VACV F11L Rev CAATTCCAATTGTTGCCTGT
VACV F17R For TGCATCTGCTCATACTCCGT
VACV F17R Rev GGGCGATGAGGGTTTATCTA
a For, forward; Rev, reverse.
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Cherry red ﬂuorescent protein (mCherry, from R. Tsien) and Guassia
luciferase (Nanolight) were separated by a “translational slip” sequence
(2A) from foot and mouth disease virus (FMDV) such that the single
transcript encoded two independent proteins. This RFP/luciferase
cassette was ampliﬁed from the expression plasmid pT-REx RFP2AGLuc
(a gift from Dr. Stojdl, Children's Hospital of Eastern Ontario) using
primers JB08.05. GCGCTGCAGAAAAATTGAAATTTTATTTTTTTTTTTTG-
GAATATAAATAATGGTGTCCAAGGGGGAGGAGGAC (Pst1 italics and vac-
cinia virus synthetic early/late (E/L) promoter is underlined) and
JB07.05 GCGCTGCAGTTAGTCACCCCCGGCTCCCTTAATC (Pst1 site itali-
cized). The ampliﬁed product was cloned into the Pst1 site of the
plasmid pBS:63KO-GFPwhich has been described previously (Barrett et
al., 2007b). This new transfer vector, pBS:63KO E/L Cherry2AGLuc, was
transfected into BGMK cells that had been previously infected with
vMyx-Lau during 1 h. Infected/transfected cells were collected 48 h
post-transfection and recombinant virus, expressingmCherry and GLuc
were puriﬁed through successive rounds of plaque puriﬁcation on
BGMK cells. For the present study, all virus stocks were grown in CV-1
cells and puriﬁed by centrifugation through a sucrose cushion and two
successive sucrose gradient sedimentations as described previously
(Earl et al., 1998).
Luciferase assays
Luciferase assays were performed using either MYXV gaussia
luciferase virus (vMyx-GLuc) or vaccinia ﬁreﬂy luciferase (VACV-FLuc).
A total of 2.5×104 cells of the indicated cell line were seeded in eachwell
ofwhite bottom96-well plate (Fisher). Cellswere infectedwith eachvirus
at a MOI of 5.0 for 1 h at 37 °C. Cells were subsequently washed with 1×
PBS and incubatedwith freshmedia. At the indicated time point, an equal
amount of either, Fireﬂy substrate BriteLite™ plus assay kit, (PerkinEl-
mer), or coelenterazine, the substrate for Gaussia luciferase, (New
England BioLabs Inc.) mixed with lysis buffer was added to the cells and
incubated for 1 min or 10 s. Bioluminescence signal intensity was
quantiﬁed on a Thermo Appliskan, 100–240 V luminometer (Thermo
Electron corp.). Each experiment was performed at least three times in
triplicate. Luciferase activity is reported in light units (LU).
Fluorescence microscopy and ﬂow cytometry
A total of 2.5×104 cells of the respective cancer cell line were
plated in each well of a 96-well plate. The following day, cells were
infected with either vMyx-GFP-TrFP, or VACV-GFP-TrFP at MOI of 0.1
and 1.0. At 24, 48, and 72 h after infection the sizes and shapes of GFP,
and TrFP foci for MYXV and plaques for VACV were observed using a
Leica DMI 6000B microscope. For FACS analysis, 72 h post-infection,
cells were harvested using 1% trypsin and ﬁxed in 2% para-
formaldehyde. Percent of GFP+ cells was quantiﬁed by using ﬂow
cytometry on a BD FACSCalibur.
Real-time PCR
Real-time PCR experiments were performed as described previously
(Bartee et al., 2009). Brieﬂy, 2 μL of total RNAwas used to prepare cDNA.
Genomic DNA was removed from total RNA, using the DNA free kit
(Ambion) according to the manufacturer's recommendations. Subse-
quently, 1 μL of the deoxynucleoside triphosphates (100 mM) and 1 μL
of random hexamer primers (50 μg/mL) were added, and the mixture
was incubated for 5 min at 65 °C. After this incubation, the tube was
allowed to cool at room temperature, and 6 μL of 5× reaction buffer, 3 μL
dithiothreitol (0.1 M), 1 μL of RNasin (Promega), and 1 μL of Superscript
III reverse transcriptase (Invitrogen) were added. The resulting mixture
was incubated for 1 h at 42 °C and then for 15 min at 72 °C. The ﬁnal
reaction was diluted 1:10 with sterile water and used for Sybr green-
based real-time PCR. Then, 4 μL of diluted cDNA was added to 21 μL ofPCR mix containing 0.5 U of Taq polymerase (NEB), 1× Thermo Pol
buffer, 0.1× Sybr green dye (Molecular Probes), 0.5× Rox reference dye
(Invitrogen), a 100 μL concentration of deoxynucleoside triphosphates
(Invitrogen), 4 mMMgCl2, (Invitrogen), 4 ng of forward primer and4 ng
of reverse primer. The resulting 25 μg reaction was run on an ABL 7300
real-time PCRmachineunder the following conditions: 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Primers used
in real-time PCR are listed in Table 2.
Virus titration
MYXV and VACV viruses were propagated and titrated by focus and
plaque formation, respectively on BSC-40 cells as described previously
(Opgenorth et al., 1992). Brieﬂy, each cell linewas seeded in a 6-well dish
during one overnight. Cells were then infected with either, vMyx-GFP-
TrFP, or VACV-GFP-TrFP at a MOI of 5.0. At the given time points post-
infection [e.g. 0 hpi (1 h after virus adsorption), 4, 8, 12, 24, and 48 hpi],
cellswereharvestedand frozen. To release thevirus, cellswere lysed three
times via freeze–thawing and then sonicated. Virus titers were deter-
mined by using the limiting dilution method on BSC-40 cells.
Virus infection at low pH
Cells were mock treated or treated with genistein at the optimal
concentration (100 μM) for 1 h at 37 °C. Subsequently, vMyx-GLuc, or
VACV-FLuc was adsorbed to the cells. Cells were then washed with
cold PBS, followed by 5 min incubation at 37 °C and pH 7.4 or pH 5.0.
Subsequently, cells were washed in neutral pH media (e.g. 7.4), and
infections were allowed to proceed for the indicated time with or
without inhibitor. Cells were then processed for luciferase activity.
When used, cycloheximide (CHX), (100 μg/mL) was added as a
control for the early protein synthesis.
Inhibition of endosomal acidiﬁcation
Cells (2×104 per well) seeded in 96 well plates were pre-treated for
1 h at 37 °C with different concentrations of baﬁlomycin A1, concanamy-
cin-A, inDMEMormock treated (no inhibitor). VACVMVwas adsorbed to
the cells at aMOI of 5.0 at 4 °C for 1 h.MYXVwas adsorbed to the cells at a
MOI of 5.0 for 1 h, at 37 °C. After virus adsorption, cells werewashedwith
PBSandthen incubatedduring5 min inneutral pH(7.4)or acidicpH(5.0),
at 37 °C. Cells were incubated at 37 °C and pH 7.4 in the presence of the
respective inhibitor. Luciferase assays were performed 2 h after virus
adsorption.
siRNA transfection
A validated siRNA against PAK1 (TCCACTGATTGCTGCAGCTAA); and a
non-targeting siRNA (NT-siRNA) were obtained from Qiagen. Shortly
before transfection, a total of 2×105HeLa cellswere plated in eachwell of
six well plates (2.3 mL volume). Cells were transfected according to
manufacturer's speciﬁcations, by mixing 50 nM of each siRNA, with
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were infectedwith recombinant, double labelﬂuorescent viruses at aMOI
of 1.0 to access virus spread. To investigate virus entry to the cells,
recombinant vMyx-GLuc, or VACV-FLuc viruseswere used at aMOI of 5.0.
For ﬂuorescence experiments the foci were evaluated 48 hpi. Luciferase
activity was measured 2 hpi.
Western blot analysis
Cells (e.g. untreated, or treatedwithdifferent inhibitors)were infected
with either vMyx-GFP-TrFP, or VACV-GFP-TrFP at a MOI of 5 for 1 h at
37 °C, andharvestedat2, 4, and24 hpi tomonitorviralproteinexpression.
Harvested cells were suspended in RIPA buffer [20 mM Tris–HCl pH 7.5,
137 mM NaCl, 15% glycerol, 20 mM NaF, 1% NP40, 10 mM NaPPi, 1%
NaV3O4, 1% phenylmethylsulphonyl ﬂuoride, 25 mM β-glycerolpho-
sphate, 0.25% sodium deoxycholate, inhibitor cocktail (Sigma-Aldrich), a
complete Mini, EDTA-free tablet (Roche) and nanopure water]. Suspen-
sions were sonicated to solubilize proteins. The levels of protein were
quantiﬁed using the Bradford assay (Bio-Rad), and 25 μg of each sample
was separated by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis. Separated proteins were transferred to a polyvinylidene ﬂuoride
(PVDF) membrane (Bio-Rad) and blocked for 1 h at room temperature
with 5% non-fat dry milk in TBST (25 mM Tris-buffered saline with 0.1%
Tween 20). Primary antibodies against each viral protein were diluted in
5% milk-TBST and incubated with the membranes for 2 h at room
temperature. After washing, membranes were incubated for 1 h at room
temperature with horseradish peroxidase-conjugated secondary anti-
bodies diluted 1/5000 in 5% milk-TBST. To monitor the expression of
PAK1, membranes were incubated overnight at 4 °C with the primary
antibody rabbit polyclonal against PAK1 (Cell Signaling Technologies),
diluted 1/1000 in 5% bovine serumalbumin-TBST.Membraneswere then
incubated for 1 hwith the respective secondary antibody in 5%milk-TBST.
Western blots were analyzed using the chemiluminescence reagent
(Millipore). Loading of equal amounts of protein from each sample was
conﬁrmed by detection of Actin. To control early and late viral protein
expression, 100 μg/mL 1.0 mg/mL of cycloheximide (CHX) and 50 μg/mL
cytosine arabinoside (AraC) were used, respectively.
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